- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Inhibrx's Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall? | 1 | Insider Monkey | ||
| 18.09. | Citizens reiterates Market Perform on Inhibrx Biosciences stock | 1 | Investing.com | ||
| 18.09. | Inhibrx Biosciences: Citizens bestätigt "Market Perform"-Rating | 1 | Investing.com Deutsch | ||
| 09.09. | Inhibrx, Eikon rise after insider buying | 2 | Seeking Alpha | ||
| 09.09. | H.C. Wainwright reiterates Inhibrx Biosciences stock rating at buy | 2 | Investing.com | ||
| 08.09. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.09. | Inhibrx Biosciences Plans Head and Neck Cancer Trial Expansion Following High Response Rates | 1 | Benzinga.com | ||
| 08.09. | Inhibrx CEO says progression-free survival data leave 'no question' about OX40 agonist's durability | 2 | FierceBiotech | ||
| INHIBRX BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
| 08.09. | Inhibrx cancer therapy outperforms Merck's Keytruda in mid-stage trial | 8 | Seeking Alpha | ||
| 08.09. | Positive Studiendaten zu Krebsmedikament beflügeln Inhibrx Aktie | 1 | Investing.com Deutsch | ||
| 08.09. | Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | 284 | PR Newswire | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen | |
| 27.08. | Citizens reiterates Market Perform on Inhibrx Biosciences stock | 2 | Investing.com | ||
| 21.08. | Stifel reiterates Buy on Inhibrx Biosciences stock, $325 target | 1 | Investing.com | ||
| 21.08. | Stifel bekräftigt Kaufempfehlung für Inhibrx Biosciences mit Kursziel von 325 US-Dollar | 1 | Investing.com Deutsch | ||
| 13.08. | Inhibrx Biosciences GAAP EPS of -$2.34 beats by $0.05 | 1 | Seeking Alpha | ||
| 13.08. | Inhibrx Biosciences, Inc.: Inhibrx Reports Second Quarter 2026 Financial Results | 214 | PR Newswire | SAN DIEGO, Aug. 13, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter... ► Artikel lesen | |
| 16.07. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.07. | Inhibrx expands credit facility to $500 million with Oxford | 3 | Investing.com | ||
| 15.06. | Inhibrx Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 15.06. | Inhibrx BLA for ozekibart accepted by FDA | 1 | Seeking Alpha |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SUMMIT THERAPEUTICS | 17,365 | +12,18 % | Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft | DJ Astrazeneca investiert 2 Mrd USD in Summit Therapeutics - Kooperation vertieft
Von Elias Schisgall
DOW JONES--Astrazeneca investiert im Rahmen einer erweiterten Partnerschaft 2 Milliarden... ► Artikel lesen | |
| QIAGEN | 38,720 | -1,01 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen vor Zahlen zum dritten Quartal mit einem Kursziel von 47 Euro auf "Buy" belassen. Jan Koch rechnet in seinem am Donnerstag... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,180 | +12,97 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
| PRAXIS PRECISION MEDICINES | 288,59 | +1,03 % | H.C. Wainwright reiterates Praxis Precision stock rating on pipeline potential | ||
| MODERNA | 168,42 | -6,13 % | 220 Millionen US-Dollar bis 2033: Warum Moderna, Capricor und NurExone auf die richtige Wirkstoffhülle setzen | ||
| CONNECT BIOPHARMA | 1,235 | +14,35 % | Connect Biopharma Holdings Limited: Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adults with COPD and Type 2 Inflammation | - Rademikibart significantly reduced the rate of treatment failure compared to placebo through one month by 81% (p=0.0122) - - Rademikibart significantly reduced the rate of new moderate to severe... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 32,120 | 0,00 % | Structure Therapeutics Inc.: Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel | SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| TANGO THERAPEUTICS | 24,510 | +0,25 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 32,770 | 0,00 % | Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA Nephropathy | TRUTAKNA, the first and only FDA-approved BAFF and APRIL inhibitor, met all prespecified endpoints, including unprecedented placebo-adjusted estimated glomerular filtration rate (eGFR) and composite... ► Artikel lesen | |
| DYNE THERAPEUTICS | 16,200 | -0,86 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) | - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion of ACHIEVE showed functional improvement versus baseline, versus placebo and versus... ► Artikel lesen | |
| CG ONCOLOGY | 72,80 | +3,17 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| TRAVERE THERAPEUTICS | 59,31 | 0,00 % | Guggenheim hebt Kursziel für Travere Therapeutics nach Patent-News an | ||
| MINERALYS THERAPEUTICS | 25,290 | +3,31 % | Mineralys konkretisiert auf Stifel-Forum Pläne zur Markteinführung von Lorundrostat | ||
| RELAY THERAPEUTICS | 17,995 | -2,09 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 40,900 | +4,31 % | Edgewise Therapeutics Reports Second Quarter 2026 Financial Results | - Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) -
- ... ► Artikel lesen |
INHIBRX BIOSCIENCES INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 102,23 Euro und damit +3,07 % im Plus. Aus der Ausschüttung der letzten 12 Monate von insgesamt 0,00 Euro errechnet sich eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INHIBRX BIOSCIENCES INC finden Sie auf Wallstreet Online.